AstraZeneca's shares rose 1.8% after its cholesterol drug AZD0780 showed a 50.7% LDL-C reduction in a Phase IIb trial, with 84% of participants meeting target levels.
AstraZeneca's Enhertu showed better response rates in biliary tract cancer patients compared to Compass Therapeutics' tovecimig, which had a 17.1% overall response rate with chemotherapy.
AstraZeneca's Calquence, combined with bendamustine and rituximab, has gained a favorable opinion from a European Medicines Agency committee for treating adults with untreated mantle cell lymphoma.
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.